1. Home
  2. TRUP vs ANAB Comparison

TRUP vs ANAB Comparison

Compare TRUP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$36.20

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$45.91

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
ANAB
Founded
2000
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
TRUP
ANAB
Price
$36.20
$45.91
Analyst Decision
Buy
Buy
Analyst Count
3
12
Target Price
$54.00
$58.09
AVG Volume (30 Days)
368.7K
501.4K
Earning Date
02-18-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,399,759,000.00
$169,467,000.00
Revenue This Year
$14.10
$135.45
Revenue Next Year
$9.54
N/A
P/E Ratio
$99.75
N/A
Revenue Growth
12.50
196.42
52 Week Low
$31.00
$12.21
52 Week High
$57.89
$52.47

Technical Indicators

Market Signals
Indicator
TRUP
ANAB
Relative Strength Index (RSI) 42.80 52.09
Support Level $34.46 $42.00
Resistance Level $36.60 $47.36
Average True Range (ATR) 1.10 2.45
MACD -0.13 -0.84
Stochastic Oscillator 39.32 35.20

Price Performance

Historical Comparison
TRUP
ANAB

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: